Literature DB >> 1399949

Comparative in-vitro activity of RP 59500.

L Verbist1, J Verhaegen.   

Abstract

The in-vitro activity of RP 59500 was compared with that of other appropriate antibiotics against 131 staphylococci, 97 streptococci, 20 enterococci, 68 Neisseria spp., 68 Haemophilus influenzae, 21 Moraxella catarrhalis and 250 Gram-negative bacilli. RP 59500 was more active than oxacillin, vancomycin and erythromycin against staphylococci (MIC 0.03-4 mg/L). RP 59500 inhibited streptococci between 0.03-1 mg/L and enterococci between 1-8 mg/L, but was less active than ampicillin and erythromycin. However, its activity remained unchanged against strains with acquired resistance to ampicillin, erythromycin and oxacillin. It was as active as ampicillin against Neisseria spp., but less active against H. influenzae and M. catarrhalis. All enterobacteria and non-fermenters were resistant to RP 59500.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1399949     DOI: 10.1093/jac/30.suppl_a.39

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  10 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Streptogramins. A unique class of antibiotics.

Authors:  J C Pechère
Journal:  Drugs       Date:  1996       Impact factor: 9.546

Review 3.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 4.  Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.

Authors:  M G Cormican; R N Jones
Journal:  Drugs       Date:  1996       Impact factor: 9.546

5.  In-vitro activity of synercid and related drugs against Streptococcus oralis isolated from septicaemia and endocarditis cases.

Authors:  A M Rafay
Journal:  J Sci Res Med Sci       Date:  2000-01

Review 6.  Quinupristin-dalfopristin.

Authors:  H M Bryson; C M Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

Review 7.  Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.

Authors:  R G Finch
Journal:  Drugs       Date:  1996       Impact factor: 9.546

8.  Identification of a streptogramin A acetyltransferase gene in the chromosome of Yersinia enterocolitica.

Authors:  A Seoane; J M García Lobo
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

9.  In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G J Malanoski; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Rickettsia phylogenomics: unwinding the intricacies of obligate intracellular life.

Authors:  Joseph J Gillespie; Kelly Williams; Maulik Shukla; Eric E Snyder; Eric K Nordberg; Shane M Ceraul; Chitti Dharmanolla; Daphne Rainey; Jeetendra Soneja; Joshua M Shallom; Nataraj Dongre Vishnubhat; Rebecca Wattam; Anjan Purkayastha; Michael Czar; Oswald Crasta; Joao C Setubal; Abdu F Azad; Bruno S Sobral
Journal:  PLoS One       Date:  2008-04-16       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.